Accredited InvestorsEmployee ShareholdersInstitutionsPrivate Companies Who We Serve Trading and Investing Data Solutions Private Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2024​Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
Solutions
Insights
About
Who We Serve
Solutions
Trading and Investing
Institutional Trading
Individual Investing
Data Solutions
Private Asset Custody
Self-Directed IRA
Insights
Private Market Reports
Market Insights
Buying and Selling Pre-IPO​
About
Log In
Sign Up
Secondary Marketplace / Trade Private Companies / Buy and Sell Grail Stock

Grail Stock

grail.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $2.02B

GRAIL is a healthcare company specializing in early cancer detection by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to developed a multi-cancer early detection blood test.

Learn more about Grail IPO

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Grail before its M&A, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Grail before its M&A.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Grail stock FAQs

plusminus

Can you buy Grail stock?

You can no longer buy Grail stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Grail stock?

To invest in a private company like Grail through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Grail stock?

You can no longer sell stock of Grail on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Grail stock?

If you hold private company shares of Grail - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Grail stock on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Grail a public company?

No, Grail is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Grail investors also invested in these private companies

Sequoia Capital China
Canada Pension Plan Investment Board
Illumina
SV Angel
PSP Investments
Hillhouse Capital Group
HuangPu River Capital

Explore private companies in the BioTech & Pharma sector

Colossal Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B
Altos Labs
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B
ADARx Pharmaceuticals
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM
Cytonics
Sector
Healthcare / BioTech & Pharma
 
 
AI Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM
Egenesis
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$333.77MM
Apnimed
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$366.58MM
Pendulum Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM
Element Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.05B

Team

Management Team

Gautam Kollu
Chief Commercial Officer
Matthew Young
Chief Financial Officer & Chief Operating Officer
Aaron Freidin
Chief Financial Officer

Board Members

Brook Byers Ph.D
Maykin Ho Ph.D
Robert Nelsen
ARCH Venture Partners
Xiangmin Cui Ph.D
Decheng Capital
Catherine Friedman
Kaye Foster
William Rastetter Ph.D
Richard Klausner MD
Illumina
Genomeweb 02/15/2022

Point32Health to Offer Grail Cancer Early Detection Test Under Pilot Program

The health plan provider will make testing available to its own employees, followed by its approximately 2.2 million commercial members.
Genomeweb 12/01/2021

Caris Life Sciences Facing FTC Lawsuit After Resisting Subpoena in Illumina, Grail Antitrust Case

Caris said it has already provided materials to Illumina and should not have to indulge a "fishing expedition for irrelevant, highly sensitive details."
Genomeweb 10/29/2021

European Commission Adopts Interim Measure to Hold Grail Separate From Illumina

The measures are legally binding for both Illumina and Grail, and compliance with them will be monitored by a trustee to be approved by the commission.
Genomeweb 09/20/2021

European Commission Objects to Illumina Pushing Through Grail Purchase, Mulls Response

European regulators called Illumina's decision to finalize its purchase of Grail "unprecedented" and said they could ultimately impose financial penalties.
Browse More Insights
Trending Companies

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.